Tacalyx GmbH raises 7m in seed funding
German Tacalyx GmbH has baged 7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans.
EMA greenlights new medicines
At its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
Danish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Researchers identify CTLA-4 response marker
German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises 39m to provide POC for nangibotide
French biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags 6.3m in Series A round
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.